Belantamab Mafodotin

BLENREP®

Verified

Overview

Belantamab Mafodotin is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC). Belantamab Mafodotin is currently FDA approved for use in multiple myeloma patients who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is investigational in all other uses. Patients can click here to locate providers of Belantamab Mafodotin (BLENREP®).

On November 22, 2022, GSK announced that it has initiated the process for withdrawal of the US marketing authorization for Blenrep following the request of the US Food and Drug Administration (FDA). This request was based on the previously announced outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the US FDA Accelerated Approval regulations. Learn More

SparkCures ID 130
Developed By GlaxoSmithKline
Brand Name Blenrep®
Generic Name Belantamab Mafodotin
Additional Names GSK2857916
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Verified
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
STOMP
View Trial
Verified
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPY
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Expanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTIN
View Trial
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomi...
DREAMM-10
View Trial
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple...
BELANTAMAB MAFODOTIN
View Trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTING
View Trial
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
BELANTAMAB MAFODOTIN COMBINATION THERAPY
View Trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTIN
View Trial
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATION
View Trial
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCE
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMAB
View Trial
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combina...
BELANTAMAB MAFODOTIN COMBINATION THERAPY
View Trial
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTS
View Trial
Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomi...
DREAMM-10
View Trial
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATION
View Trial
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCE
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
STOMP
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPY
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple...
BELANTAMAB MAFODOTIN
View Trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATION
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combina...
BELANTAMAB MAFODOTIN COMBINATION THERAPY
View Trial
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTS
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
STOMP
View Trial
Verified
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPY
View Trial
Verified
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
DREAMM13
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Expanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTIN
View Trial
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTING
View Trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...
BELANTAMAB MAFODOTIN
View Trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...
ISABELA
View Trial
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTIN
View Trial
Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATION
View Trial
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMAB
View Trial
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combina...
BELANTAMAB MAFODOTIN COMBINATION THERAPY
View Trial
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTS
View Trial
Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Verified
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
BELANTAMAB MAFODOTIN
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma

February 07, 2024

In the primary endpoint of progression-free survival (PFS), a statistically significant and clinically meaningful improvement was observed with the belantamab mafodotin combination (n=243), showing a 59% reduction in the risk of disease progression or death (hazard ratio [HR]: 0.41 [95% confidence interval (CI): 0.31-0.53], p-value<0.00001) compared to the daratumumab combination (n=251). With a median follow-up of 28.2 months, the median PFS was 36.6 months (95% CI: 28.4-not reached [NR]) with the belantamab mafodotin combination compared to 13.4 months (11.1-17.5) in the daratumumab combination. The PFS effect was observed across all prespecified subgroups, including those who were refractory to lenalidomide and those with high-risk cytogenetics. The safety and tolerability profile of the belantamab mafodotin combination was consistent with the known profile of the individual agents.

Read More

Resources

GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization

November 22, 2022

Read More
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapse...

August 06, 2020

Read More
Blenrep delays disease progression by nearly 3X versus Darzalex

February 13, 2024

Read More
Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapse...

November 28, 2023

Read More
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed...

November 27, 2023

Read More
Belantamab Mafodotin Induces Deep and Durable Responses in R/R Myeloma

September 29, 2022

Read More
Belantamab Mafodotin Elicits Deep, Durable Responses in Heavily Pretreated Relapsed/Refractory My...

December 06, 2020

Read More
FDA Panel Supports Belantamab Mafodotin for Relapsed/Refractory Myeloma

July 14, 2020

Read More
GlaxoSmithKline : GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for...

June 19, 2020

Read More
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients...

January 21, 2020

Read More
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate...

June 27, 2019

Read More
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in p...

March 21, 2019

Read More
GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Mye...

December 12, 2017

Read More
BLENREP® Certified Participant Locator

Patients can locate providers of Belantamab Mafodotin (BLENREP®) based on location/zip code.

Learn More
GSK Compassionate Use (Expanded Access) Request Portal

GSK recognises that there may be circumstances when it is appropriate for Healthcare Professionals to give their patients Investigational medicines to treat life threatening or seriously debilitating diseases/conditions where no satisfactory alternatives exist.

Learn More
SparkCures Verified

SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners